Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir

- PMLiVE

Gilead recalls Vistide due to foreign particles

Affected batch of AIDS symptom treatment sold in the US, Europe and Canada

- PMLiVE

Anker Lundemose appointed CEO of Bionor Pharma

Will lead efforts to develop and commercialise HIV vaccines

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

- PMLiVE

Sexual health apps fail to attract smartphone users

HIV and STD apps not fulfilling their potential to assist with prevention and care

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

- PMLiVE

Streaming Well and Terrence Higgins Trust launch HIV education series

Online videos target young people in Britain

- PMLiVE

Efforts to curb HIV must be stepped up, says report

HIV/AIDS advocacy group ONE pushes for more funding to end epidemic

- PMLiVE

Gilead posts strong data for all-oral hepatitis C treatment

Achieves sustained virologic response in 78 per cent of participants

- PMLiVE

Gilead advances HIV drug into phase III

The treatment is a chemical variant of Gilead's successful HIV drug Viread

- PMLiVE

GSK, Pfizer and Shionogi rewrite HIV joint venture terms

Comes ahead of first regulatory submissions for lead drug candidate dolutegravir

- PMLiVE

Indonesia breaks seven HIV, hepatitis drug patents

Merck & Co, GSK, Gilead, Abbott and BMS all effected

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links